Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib + WBRT or SRS in BRAF+ Melanoma with Brain Metastases
NCT02145910Phase 1Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of vemurafenib in melanoma (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Status: withdrawn.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02145910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145910.